Effects of food neophobia on visual attention and sensory acceptance of ethnic-flavored foods von Samant, Shilpa S., Hanson, Aubrie D., Asare, Ruby, Nichols, Dalton S., Nna-Mba, Jean-Pierre, Seo, Han-Seok

Volltext

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial von Pusztai, Lajos, Yau, Christina, Wolf, Denise M., Han, Hyo S., Du, Lili, Wallace, Anne M., String-Reasor, Erica, Boughey, Judy C., Chien, A. Jo, Elias, Anthony D., Beckwith, Heather, Nanda, Rita, Albain, Kathy S., Clark, Amy S., Kemmer, Kathleen, Kalinsky, Kevin, Isaacs, Claudine, Thomas, Alexandra, Shatsky, Rebecca, Helsten, Theresa L., Forero-Torres, Andres, Liu, Minetta C., Brown-Swigart, Lamorna, Petricoin, Emmanuel F., Wulfkuhle, Julia D., Asare, Smita M., Wilson, Amy, Singhrao, Ruby, Sit, Laura, Hirst, Gillian L., Berry, Scott, Sanil, Ashish, Asare, Adam L., Matthews, Jeffrey B., Perlmutter, Jane, Melisko, Michelle, Rugo, Hope S., Schwab, Richard B., Symmans, W. Fraser, Yee, Doug, van’t Veer, Laura J., Hylton, Nola M., DeMichele, Angela M., Berry, Donald A., Esserman, Laura J.

Volltext

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients von Yau, Christina, van der Noordaa, Marieke, Shad, Sonal, de Croze, Diane, Hamy, Anne-Sophie, Laé, Marick, Reyal, Fabien, Sonke, Gabe S, Steenbruggen, Tessa G, van Seijen, Maartje, Wesseling, Jelle, del Monte-Millán, Maria, López-Tarruella, Sara, Albain, Kathy S., Asare, Smita M., Balassanian, Ron, Beckwith, Heather, Berry, Scott M., Berry, Donald A., Boughey, Judy C., Buxton, Meredith B., Chen, Yunn-Yi, Chen, Beiyun, Clark, Amy S., Clennell, Julia L., DeMichele, Angela M., Duan, Xiuzhen, Edmiston, Kirsten K., Ellis, Erin D., Esserman, Laura L., Euhus, David M., Fan, Fang, Feldman, Michael D, Han, Hyo S., Haugen, Patricia, Helsten, Teresa, Hylton, Nola M., Isaacs, Claudine, Kemmer, Kathleen, Khazai, Laila, Klein, Molly E., Krings, Gregor, Leyland-Jones, Brian, Liu, Minetta C., Lo, Shelly, Lu, Janice, Magliocco, Anthony, Melisko, Michelle E., Mhawech-Fauceglia, Paulette, Moulder, Stacy L., Murthy, Rashmi K., Nanda, Rita, Ocal, Idris T., Olopade, Olufunmilayo, Pambuccian, Stefan, Paoloni, Melissa, Park, John W., Perlmutter, Jane, Peterson, Garry, Rendi, Mara, Rugo, Hope S., Sams, Sharon, Sattar, Husain, Schwab, Richard B., Singhrao, Ruby, Steeg, Katherine, Stringer-Reasor, Erica, Symmans, W. Fraser, Tripathy, Debasish, Troxell, Megan L., van't Veer, Laura J., Venters, Sara J., Vinh, Tuyethoa, Viscusi, Rebecca K., Wallace, Anne M., Wei, Shi, Wilson, Amy, Yau, Christina, Zeck, Jay C., Boughey, Judy C, Goetz, Matthew P, Hoskin, Tanya, Gould, Rebekah, Edge, Stephen B, Abraham, Jean E, Bartlett, John M S, Caldas, Carlos, Dunn, Janet, Hayward, Larry, Provenzano, Elena, Mackintosh, Lorna, Fan, Fang, Schwensen, Kelsey, Sharma, Priyanka, DeMichele, Angela M, Cole, Kimberly, Pusztai, Lajos, Kim, Mi-Ok, van 't Veer, Laura J, Symmans, W Fraser

Volltext

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial von Clark, Amy S., Yau, Christina, Wolf, Denise M., Petricoin, Emanuel F., van ‘t Veer, Laura J., Yee, Douglas, Moulder, Stacy L., Wallace, Anne M., Chien, A. Jo, Isaacs, Claudine, Boughey, Judy C., Albain, Kathy S., Kemmer, Kathleen, Haley, Barbara B., Han, Hyo S., Forero-Torres, Andres, Elias, Anthony, Lang, Julie E., Ellis, Erin D., Yung, Rachel, Tripathy, Debu, Nanda, Rita, Wulfkuhle, Julia D., Brown-Swigart, Lamorna, Gallagher, Rosa I., Helsten, Teresa, Roesch, Erin, Ewing, Cheryl A., Alvarado, Michael, Crane, Erin P., Buxton, Meredith, Clennell, Julia L., Paoloni, Melissa, Asare, Smita M., Wilson, Amy, Hirst, Gillian L., Singhrao, Ruby, Steeg, Katherine, Asare, Adam, Matthews, Jeffrey B., Berry, Scott, Sanil, Ashish, Melisko, Michelle, Perlmutter, Jane, Rugo, Hope S., Schwab, Richard B., Symmans, W. Fraser, Hylton, Nola M., Berry, Donald A., Esserman, Laura J., DeMichele, Angela M.

Volltext

MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers i... von Chien, A Jo, Tripathy, Debasish, Albain, Kathy S, Symmans, W Fraser, Rugo, Hope S, Melisko, Michelle E, Wallace, Anne M, Schwab, Richard, Helsten, Teresa, Forero-Torres, Andres, Stringer-Reasor, Erica, Ellis, Erin D, Kaplan, Henry G, Nanda, Rita, Jaskowiak, Nora, Murthy, Rashmi, Godellas, Constantine, Boughey, Judy C, Elias, Anthony D, Haley, Barbara B, Kemmer, Kathleen, Isaacs, Claudine, Clark, Amy S, Lang, Julie E, Lu, Janice, Korde, Larissa, Edmiston, Kirsten K, Northfelt, Donald W, Viscusi, Rebecca K, Yee, Douglas, Perlmutter, Jane, Hylton, Nola M, Van't Veer, Laura J, DeMichele, Angela, Wilson, Amy, Peterson, Garry, Buxton, Meredith B, Paoloni, Melissa, Clennell, Julia, Berry, Scott, Matthews, Jeffrey B, Steeg, Katherine, Singhrao, Ruby, Hirst, Gillian L, Sanil, Ashish, Yau, Christina, Asare, Smita M, Berry, Donald A, Esserman, Laura J

Volltext

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer von Yee, Douglas, Isaacs, Claudine, Wolf, Denise M., Yau, Christina, Haluska, Paul, Giridhar, Karthik V., Forero-Torres, Andres, Jo Chien, A., Wallace, Anne M., Pusztai, Lajos, Albain, Kathy S., Ellis, Erin D., Beckwith, Heather, Haley, Barbara B., Elias, Anthony D., Boughey, Judy C., Kemmer, Kathleen, Yung, Rachel L., Pohlmann, Paula R., Tripathy, Debu, Clark, Amy S., Han, Hyo S., Nanda, Rita, Khan, Qamar J., Edmiston, Kristen K., Petricoin, Emanuel F., Stringer-Reasor, Erica, Falkson, Carla I., Majure, Melanie, Mukhtar, Rita A., Helsten, Teresa L., Moulder, Stacy L., Robinson, Patricia A., Wulfkuhle, Julia D., Brown-Swigart, Lamorna, Buxton, Meredith, Clennell, Julia L., Paoloni, Melissa, Sanil, Ashish, Berry, Scott, Asare, Smita M., Wilson, Amy, Hirst, Gillian L., Singhrao, Ruby, Asare, Adam L., Matthews, Jeffrey B., Hylton, Nola M., DeMichele, Angela, Melisko, Michelle, Perlmutter, Jane, Rugo, Hope S., Fraser Symmans, W., van‘t Veer, Laura J., Berry, Donald A., Esserman, Laura J.

Volltext

Abstract P2-12-06: The clinical benefit index: A pilot study integrating treatment efficacy and quality of life in oncology clinical trials von Basu, Amrita, Philip, Errol J., Dewitt, Barry, Hanmer, Janel, Chattopadhyay, Aheli, Yau, Christina, Asare, Smita, Digiorgio, Karyn, Singhrao, Ruby, Asare, Adam, Perlmutter, Jane, Melisko, Michelle, Esserman, Laura

Volltext

Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer von Rugo, Hope S, Campbell, Mike, Yau, Christina, Jo Chien, A, Wallace, Anne M, Isaacs, Claudine, Boughey, Judy C, Han, Hyo S, Buxton, Meredith, Clennell, Julia L, Asare, Smita M, Steeg, Katherine, Wilson, Amy, Singhrao, Ruby, Matthews, Jeffrey B, Perlmutter, Jane, Fraser Symmans, W, Hylton, Nola M, DeMichele, Angela M, Yee, Douglas, Van't Veer, Laura J, Berry, Donald A, Esserman, Laura J

Volltext

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer von Lang, Julie E., Forero-Torres, Andres, Yee, Douglas, Yau, Christina, Wolf, Denise, Park, John, Parker, Barbara A., Chien, A. Jo, Wallace, Anne M., Murthy, Rashmi, Albain, Kathy S., Ellis, Erin D., Beckwith, Heather, Haley, Barbara B., Elias, Anthony D., Boughey, Judy C., Yung, Rachel L., Isaacs, Claudine, Clark, Amy S., Han, Hyo S., Nanda, Rita, Khan, Qamar J., Edmiston, Kristen K., Stringer-Reasor, Erica, Price, Elissa, Joe, Bonnie, Liu, Minetta C., Brown-Swigart, Lamorna, Petricoin, Emanuel F., Wulfkuhle, Julia D., Buxton, Meredith, Clennell, Julia L., Sanil, Ashish, Berry, Scott, Asare, Smita M., Wilson, Amy, Hirst, Gillian L., Singhrao, Ruby, Asare, Adam L., Matthews, Jeffrey B., Melisko, Michelle, Perlmutter, Jane, Rugo, Hope S., Symmans, W. Fraser, van ‘t Veer, Laura J., Hylton, Nola M., DeMichele, Angela M., Berry, Donald A., Esserman, Laura J.

Volltext

Abstract P3-11-02: Evaluation of patritumab/paclitaxel/trastuzumab over standard paclitaxel/trastuzumab in early stage, high-risk HER2 positive breast cancer: Results from the neoa... von Helsten, Teresa L, Lo, Shelly S, Yau, Christina, Kalinsky, Kevin, Elias, Anthony D, Wallace, Anne M, Chien, A. Jo, Lu, Janice, Lang, Julie E, Albain, Kathy S, Stringer-Reasor, Erica, Clark, Amy S, Boughey, Judy C, Ellis, Erin D, Yee, Douglas, DeMichele, Angela, Isaacs, Claudine, Perlmutter, Jane, Rugo, Hope S, Schwab, Richard, Hylton, Nola M., Symmans, W. Fraser, Melisko, Michelle E, van't Veer, Laura J, Wilson, Amy, Singhrao, Ruby, Asare, Smita M, Sanil, Ashish, Berry, Donald A, Esserman, Laura J

Volltext

Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL von Pusztai, Lajos, Han, Hyo S., Yau, Christina, Wolf, Denise, Wallace, Anne M., Shatsky, Rebecca, Helsten, Teresa, Boughey, Judy C., Haddad, Tufia, Stringer-Reasor, Erica, Falkson, Carla, Chien, A. Jo, Mukhtar, Rita, Elias, Anthony, Virginia, Borges, Nanda, Rita, Yee, Douglas, Kalinsky, Kevin, Albain, Kathy S., Muller, Aixa Soyano, Kemmer, Kathleen, Clark, Amy S., Isaacs, Claudine, Thomas, Alexandra, Hylton, Nola, Symmans, W. Fraser, Perlmutter, Jane, Melisko, Michelle, Rugo, Hope S., Schwab, Richard, Wilson, Amy, Singhrao, Ruby, Asare, Smita, van't Veer, Laura J., DeMichele, Angela M., Sanil, Ashish, Berry, Donald A., Esserman, Laura J.

Volltext

Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL von Liu, Minetta C., Robinson, Patricia A, Yau, Christina, Wallace, Anne M, Chien, A. Jo, Stringer-Reasor, Erica, Nanda, Rita, Yee, Douglas, Albain, Kathy S, Boughey, Judy C, Han, Heather S, Elias, Anthony D, Kalinsky, Kevin, Clark, Amy S, Kemmer, Kathleen, Isaacs, Claudine, Lang, Julie E, Lu, Janice, Sanft, Tara, DeMichele, Angela, Hylton, Nola M, Melisko, Michelle E, Perlmutter, Jane, Rugo, Hope S, Schwab, Richard, Symmans, W. Fraser, van't Veer, Laura J, Haugen, Patricia K, Wilson, Amy, Singhrao, Ruby, Asare, Smita, Sanil, Ashish, Berry, Donald A, Esserman, Laura J

Volltext

Abstract CT136: Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL von Schwab, Richard, Clark, Amy S., Yau, Christina, Hylton, Nola, Li, Wen, Wolfe, Denise, Chien, A Jo, Wallace, Anne M., Forero-Torres, Andres, Stringer-Reasor, Erica, Nanda, Rita, Jaskowiak, Nora, Boughey, Judy, Haddad, Tufia, Han, Heather S., Lee, Catherine, Albain, Kathy, Isaacs, Claudine, Elias, Anthony D., Ellis, Erin D., Shah, Payal, Lang, Julie E., Lu, Janice, Tripathy, Debasish, Kemmer, Kathleen, Yee, Douglas, Haley, Barbara, Majure, Melanie, Roesch, Erin, Vaklavas, Christos, Ewing, Cheryl, Helsten, Teresa, Symmans, W Fraser, Perlmutter, Jane, Rugo, Hope S., Melisko, Michelle, Wilson, Amy, Singhrao, Ruby, Veer, Laura van 't, DeMichele, Angela, Asare, Smita, Berry, Don, Esserman, Laura J.

Volltext